Results 261 to 270 of about 168,862 (349)

Tumor Lysis Syndrome Triggered by Acalabrutinib in Chronic Lymphocytic Leukemia (CLL): Diagnostic and Therapeutic Implications. [PDF]

Cureus
Fadi M, Lahlou FA, El Ouafa Y, Chahdi H, Bouanani N.   +4 more
europepmc   +1 more source

3R gene expression in chronic lymphocytic leukemia reveals insight into disease evolution

, 2016
Srđana Grgurević, Laure Berquet, Anne Quillet‐Mary, G Laurent, Christian Récher, Loïc Ysebaert, Christophe Cazaux, Jean‐Sébastien Hoffmann   +7 more
openalex   +1 more source

Humoral and functional SARS‐CoV‐2‐specific T‐cell responses elicited in chronic lymphocytic leukaemia patients with GEO‐CM04S1 a synthetic MVA‐vectored COVID‐19 vaccine

British Journal of Haematology, EarlyView.
Sandra Ortega‐Francisco, Maria Teresa Prudente de Aquino, Corinna La Rosa, Flavia Chiuppesi, Miguel‐Angel Gutierrez, Jacqueline Miller, Jing Li, Jada Mack‐Onyeike, Yifei Zhou, Qiao Zhou, Teodora Kaltcheva, Angela Patterson, Shannon Dempsey, Sandra Thomas, Katrin Tiemann, Dongyun Yang, Wasima Rida, Felix Wussow, Kelly McKee, Randy Taplitz, Erica Raiden, Tanya Siddiqi, Steven Rosen, Don J. Diamond, Alexey Danilov   +24 more
wiley   +1 more source

The Role of SAMHD1 in Viral Resistance and Transduction Efficiency Challenges in Pediatric Hematological Malignancies: Mechanistic Insights and Clinical Perspectives

European Journal of Haematology, EarlyView.
SAMHD1 regulates intracellular dNTP pools, influencing lentiviral transduction, gene therapy efficiency, and disease progression in pediatric hematological malignancies. Integrated bioinformatics and targeted strategies, including CRISPR and pharmacological inhibition, highlight its therapeutic potential.
Waseem Alzamzami
wiley   +1 more source

Real-World Treatment Patterns and Outcomes of Zanubrutinib in Chronic Lymphocytic Leukemia and Small Lymphocytic Leukemia (CLL/SLL). [PDF]

Cancer Med
Krackeler ML, Chee BH, Orchanian AK, Liu R, Law L, Zhu S, Zhu Z, Sakoda LC, Buchanan S, Massoudi M, Lopez A, Tavakoli J.   +11 more
europepmc   +1 more source

Validation of prognostic scores in patients with HIV‐related diffuse large B‐cell lymphoma: The value of peripheral blood parameters—A study from the Spanish Lymphoma Group GELTAMO

British Journal of Haematology, EarlyView.
Maria Huguet, Mireia Morgades, Alfredo Rivas‐Delgado, Mariana Bastos‐Oreiro, Raúl Córdoba, Antonio Salar, Fátima de la Cruz‐Vicente, Miguel Alcoceba, Blanca Ferrer‐Lores, Ana Jiménez‐Ubieto, Antonio Gutiérrez, María Infante, Sofía Huerga, Pau Abrisqueta, David Cruz, Carlos Montalbán, Ana Muntañola, Sonia González‐de Villambrosia, Josep‐Maria Ribera, José‐Tomás Navarro   +19 more
wiley   +1 more source

Cardiovascular Challenges in Chronic Lymphocytic Leukemia (CLL) Patients Undergoing Bruton Tyrosine Kinase (BTK) Inhibitor Therapy

European Journal of Haematology, EarlyView.
ABSTRACT Background/Objectives Bruton tyrosine kinase inhibitors (BTKis) have revolutionized treatment for chronic lymphocytic leukemia (CLL), but cardiovascular (CV) toxicities pose significant challenges. Second‐generation BTKis offer improved target specificity, yet CV risks persist.
Stefano Oliva, Stefano Molica
wiley   +1 more source

From Sample to Sequencing: The Importance of Pre-Analytical Sample Treatment in NGS Analysis of Patients with Chronic Lymphocytic Leukemia. [PDF]

Cancers (Basel)
Suver Stević M, Holik H, Periša V, Marczi S, Kolobarić N, Samardžija M.   +5 more
europepmc   +1 more source

T‐cell immunomodulation occurs with different time kinetics during acalabrutinib and zanubrutinib therapy in chronic lymphocytic leukaemia

British Journal of Haematology, EarlyView.
Maria L. Andersson, Olina Lind, Kia Heimersson, Anna Berglöf, Teresa del Peso Santos, Lucía Peña‐Pérez, Qing Wang, Tom A. Mulder, Rula Zain, Robert Månsson, Richard Rosenquist, C. I. Edvard Smith, Anders Österborg, Marzia Palma   +13 more
wiley   +1 more source

Dasatinib Produces Lengthy Remissions of Extramedullary Leukemia: A Retrospective Observational Study

European Journal of Haematology, EarlyView.
ABSTRACT Since 2004, patients receiving imatinib with relapse in non‐marrow sites were given dasatinib to preserve control of leukemic marrow. Remissions in CNS and other organs began to be reported and are continuously observed to present. With resistance to one BCR::ABL1 tyrosine kinase inhibitor and sensitivity to a dual BCR::ABL1/SRC inhibitor ...
I. Cunningham, R. A. Fisher, J. Yang, Y. Guo, U. Bommhardt   +4 more
wiley   +1 more source